Farrow Jeffrey S 4

What Happened
Jeffrey S. Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals (TARS), sold a total of 6,430 shares in three open-market transactions to cover tax withholding tied to vested Restricted Stock Units (RSUs). The sales occurred 3/17–3/19/2026 at the following prices and proceeds: 2,111 shares @ $69.42 = $146,546; 2,133 shares @ $68.71 = $146,558; 2,186 shares @ $67.00 = $146,462. Total proceeds were about $439,566. These were sales (not purchases) executed as part of a mandatory "sell to cover" for taxes, not discretionary trades.

Key Details

• Transaction dates and prices: 2026-03-17 (2,111 @ $69.42), 2026-03-18 (2,133 @ $68.71), 2026-03-19 (2,186 @ $67.00).
• Total shares sold: 6,430; total proceeds: ~$439,566.
• Shares owned after transaction: Not specified in this filing.
• Footnote: Sale was to satisfy tax withholding on RSU vesting per issuer-mandated "sell to cover" (not a discretionary sale by the reporting person).
• Filing timeliness: Form 4 filed 2026-03-19; transactions reported within required filing window (timely).

Context
These transactions were tax-withholding sales tied to RSU settlement — a routine administrative step common when awards vest. Such "sell to cover" transactions are not typically interpreted as an insider expressing a view on the company's stock price.